The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy
Abstract
IMPORTANCE: Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cord that leads to blindness and paralysis. Effective immunosuppression is the standard of care for relapse prevention. OBJECTIVE: To compare the relapse and treatment failure rates among patients receiving the 3 most common forms of immunosuppression for NMO: azathioprine, mycophenolate mofetil, and rituximab. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective, multicenter analysis of relapses in 90 patients with NMO and NMO spectrum disorder treated with azathioprine, mycophenolate, and/or rituximab at the Mayo Clinic and the Johns Hopkins Hospital during the past 10 years. MAIN OUTCOME AND MEASURE: Annualized relapse rates. RESULTS: Rituximab reduced the relapse rate up to 88.2%, with 2 in 3 patients achieving complete remission. Mycophenolate reduced the relapse rate by up to 87.4%, with a 36% failure rate. Azathioprine reduced the relapse rate by 72.1% but had a 53% failure rate despite concurrent use of prednisone. CONCLUSIONS AND RELEVANCE: Initial treatment with rituximab, mycophenolate, and, to a lesser degree, azathioprine significantly reduces relapse rates in NMO and NMO spectrum disorder patients. Patients for whom initial treatment fails often achieve remission when treatment is switched from one to another of these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
Self-citationAn open label study of the effects of rituximab in neuromyelitis optica
Cree, B. A. C., Lamb, S., Morgan, K., Chen, A., Waubant, E., & Genain, C. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Pittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395
Self-citationMandler, R. N., Ahmed, W., & Dencoff, J. E. (1998) · Neurology · doi:10.1212/wnl.51.4.1219 · Cited by 366
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Jacob, A., Matiello, M., Weinshenker, B. G., Wingerchuk, D. M., Lucchinetti, C., Shuster, E., Carter, J., Keegan, B. M., Kantarci, O. H., & Pittock, S. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.175 · Cited by 308
Self-citationLong-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H. L., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
Kim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Kleiter, I. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.216 · Cited by 294
Min, J.-H., Kim, B. J., & Lee, K. H. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511431973 · Cited by 280
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Clifford, D. B., Ances, B., Costello, C., Rosen-Schmidt, S., Andersson, M., Parks, D., Perry, A., Yerra, R., Schmidt, R., Alvarez, E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.103 · Cited by 278
Cited by
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Self-citationDamato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
Neuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Self-citationNeuromyelitis optica spectrum disorders
Huda, S., Whittam, D., Bhojak, M., Chamberlain, J., Noonan, C., Jacob, A., & Kneen, R. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-2-169 · Cited by 283
Metadata
- Authors
- Mealy, M. A., Wingerchuk, D. M., Palace, J., Greenberg, B. M., & Levy, M.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-03-01
- Volume
- 71
- Issue
- 3
- Pages
- 324
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2014893669
- Cited by
- 302
- References
- 15
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. https://app.cochat.ai/papers/10.1001/jamaneurol.2013.5699
- The paper
- Mealy, M. A., Wingerchuk, D. M., Palace, J., Greenberg, B. M., & Levy, M. (2014). Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2013.5699
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
